Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Jiangsu Alphamab Biopharmaceuticals Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, keeping the recorded prosecution activity concentrated. LEE, YIE CHIA is the busiest examiner, with 1 pending matter.
This structure allows counsel to focus on one outstanding action and one biotechnology and pharmaceutical examination setting. There is no recorded need to reconcile multiple examiner positions or art-unit practices. The response can therefore align claim language, technical evidence, and disclosure support to the issues raised by the identified examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | LEE, YIE CHIA | 33d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | LEE, YIE CHIA | 1642 | §103Other | Final Rejection | 33d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Alphamab Biopharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yie Chia Lee has the most, with 1 of Jiangsu Alphamab Biopharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
